Research Progress on the Factors Influencing the Recurrence of Atrial Fibrillation after Radiofrequency Ablation

Xingyu Zhou; Huangjun Liu; Xin Yu

doi:10.54097/tknt6f93

Authors

Xingyu Zhou
Huangjun Liu
Xin Yu

DOI:

https://doi.org/10.54097/tknt6f93

Keywords:

Atrial Fibrillation, Radiofrequency Ablation, Recurrence

Abstract

Catheter radiofrequency ablation is an important treatment for atrial fibrillation (AF) at present. However, the recurrence rate of AF after catheter radiofrequency ablation is relatively high. Factors affecting postoperative recurrence include age, gender, type and duration of AF, ablation strategy, characteristics of the left atrium, electrocardiographic parameters, biomarkers, and coexisting diseases. Assessing the risk of postoperative recurrence in AF patients by these factors and developing a reasonable treatment strategy based on the assessment can help improve the therapeutic benefits of AF patients.

Downloads

Download data is not yet available.

References

[1] Sygitowicz G, Maciejak-Jastrzębska A, Sitkiewicz D. A review of the molecular mechanisms underlying cardiac fibrosis and atrial fibrillation[J]. Journal of Clinical Medicine, 2021, 10(19): 4430.

[2] Wang Z, Lai Y, Wang Y, et al. Very-early symptomatic recurrence is associated with late recurrence after radiofrequency ablation of atrial fibrillation[J]. Europace, 2023, 25(7): euad189.

[3] Ma Changsheng, Society of Cardiology, Chinese Medical Association, Heart Rhythm Society, Chinese Society of Biomedical Engineering, et al. Chinese guidelines for diagnosis and treatment of atrial fibrillation [J]. Chinese Journal of Cardiology, 2023, 51(6): 572-618.

[4] Luo Y, Tang Y, Huang W, et al. Age, creatinine, and ejection fraction (ACEF) score as predictive values for late non-valvular atrial fibrillation recurrence after radiofrequency ablation[J]. Clinical and Experimental Hypertension, 2023, 45(1): 2207784.

[5] Bahnson T D, Giczewska A, Mark D B, et al. Association between age and outcomes of catheter ablation versus medical therapy for atrial fibrillation: results from the CABANA trial[J]. Circulation, 2022, 145(11): 796-804.

[6] Tanaka N, Inoue K, Kobori A, et al. Sex differences in atrial fibrillation ablation outcomes: insights from a large-scale multicentre registry[J]. EP Europace, 2020, 22(9): 1345-1357.

[7] Cheng X, Hu Q, Gao L, et al. Sex-related differences in catheter ablation of atrial fibrillation: a systematic review and meta-analysis[J]. EP Europace, 2019, 21(10): 1509-1518.

[8] Mizuno H,Sex Difference in Clinical Recurrence After Catheter Ablation in Young Patients With Atrial Fibrillation - What Is the Underlying Mechanism?[J] .Circ J, 2018, 82: 2244-2245.

[9] Balk E M, Garlitski A C, ALSHEIKH‐ALI A A, et al. Predictors of atrial fibrillation recurrence after radiofrequency catheter ablation: a systematic review[J]. Journal of cardiovascular electrophysiology, 2010, 21(11): 1208-1216.

[10] Baek Y S, Choi J I, Kim Y G, et al. Atrial substrate underlies the recurrence after catheter ablation in patients with atrial fibrillation[J]. Journal of Clinical Medicine, 2020, 9(10): 3164.

[11] Chew D S, Black-Maier E, Loring Z, et al. Diagnosis-to-ablation time and recurrence of atrial fibrillation following catheter ablation: a systematic review and meta-analysis of observational studies[J]. Circulation: Arrhythmia and Electrophysiology, 2020, 13(4): e008128.

[12] Charitakis E, Metelli S, Karlsson L O, et al. Comparing efficacy and safety in catheter ablation strategies for atrial fibrillation: a network meta-analysis[J]. BMC medicine, 2022, 20(1): 193.

[13] Jim M N, Lim B, Yu H T, et al. Long‐term outcome of additional superior vena cava to septal linear ablation in catheter ablation of atrial fibrillation[J]. Journal of the American Heart Association, 2019, 8(22): e013985.

[14] Schilling R, Dhillon G S, Tondo C, et al. Safety, effectiveness, and quality of life following pulmonary vein isolation with a multi-electrode radiofrequency balloon catheter in paroxysmal atrial fibrillation: 1-year outcomes from SHINE[J]. EP Europace, 2021, 23(6): 851-860.

[15] Sutter J S, Lokhnygina Y, Daubert J P, et al. Safety and efficacy outcomes of left atrial posterior wall isolation compared to pulmonary vein isolation and pulmonary vein isolation with linear ablation for the treatment of persistent atrial fibrillation[J]. American Heart Journal, 2020, 220: 89-96.

[16] Berruezo A, Tamborero D, Mont L, et al. Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation[J]. European heart journal, 2007, 28(7): 836-841.

[17] Wang Q, Zhuo C, Shang Y, et al. U-Shaped Relationship Between Left Atrium Size on Echocardiography and 1-Year Recurrence of Atrial Fibrillation After Radiofrequency Catheter Ablation―Prognostic Value Study―[J]. Circulation Journal, 2019, 83(7): 1463-1471.

[18] Ghafouri K, Franke K B, Foo F S, et al. Clinical utility of cardiac magnetic resonance imaging to assess the left atrium before catheter ablation for atrial fibrillation-A systematic review and meta-analysis[J]. International journal of cardiology, 2021, 339: 192-202.

[19] Koutalas E, Kallergis E, Nedios S, et al. P-wave duration as a marker of atrial remodeling in patients referred to ablation for atrial fibrillation: a new stratification tool emerging?[J]. Hellenic Journal of Cardiology, 2023, 73: 53-60.

[20] Miao Y, Xu M, Yang L, et al. Investigating the association between P wave duration and atrial fibrillation recurrence after radiofrequency ablation in early persistent atrial fibrillation patients[J]. International journal of cardiology, 2022, 351: 48-54.

[21] Intzes S, Zagoridis K, Symeonidou M, et al. P-wave duration and atrial fibrillation recurrence after catheter ablation: a systematic review and meta-analysis[J]. Europace, 2023, 25(2): 450-459.

[22] Miake J, Kato M, Ogura K, et al. Pre-ablation levels of brain natriuretic peptide are independently associated with the recurrence of atrial fibrillation after radiofrequency catheter ablation in patients with nonvalvular atrial fibrillation[J]. Heart and Vessels, 2019, 34: 517-526.

[23] Jiang H, Wang W, Wang C, et al. Association of pre-ablation level of potential blood markers with atrial fibrillation recurrence after catheter ablation: a meta-analysis[J]. Ep Europace, 2017, 19(3): 392-400.

[24] Kawaji T, Shizuta S, Aizawa T, et al. Prognostic Importance of B-Type Natriuretic Peptide Level in Patients Undergoing Catheter Ablation for Atrial Fibrillation[J]. Circulation Journal, 2023, 87(12): 1730-1739.

[25] Okada M, Tanaka N, Tanaka K, et al. Usefulness of post-procedural plasma brain natriuretic peptide levels to predict recurrence after catheter ablation of atrial fibrillation in patients with left ventricular systolic dysfunction[J]. The American Journal of Cardiology, 2021, 144: 67-76.

[26] Huang T, An Z, Huang Z, et al. Serum albumin and cardiovascular disease: a Mendelian randomization study[J]. BMC Cardiovascular Disorders, 2024, 24(1): 196.

[27] Chen B, Wang C, Li W. Serum albumin levels and risk of atrial fibrillation: a Mendelian randomization study[J]. Frontiers in Cardiovascular Medicine, 2024, 11: 1385223.

[28] Peng Z, Wen‐Heng L, Qing Z, et al. Risk factors for late recurrence in patients with nonvalvular atrial fibrillation after radiofrequency catheter ablation[J]. Annals of Noninvasive Electrocardiology, 2022, 27(2): e12924.

[29] Der-Yuan C, Lin C H, Chen Y M, et al. Risk of Atrial Fibrillation or Flutter Associated with Periodontitis: A Nationwide, Population-Based, Cohort Study[J]. PLOS ONE, 2016, 11(10): 1-14.

[30] Isola G, Polizzi A, Santonocito S, et al. Periodontitis activates the NLRP3 inflammasome in serum and saliva[J]. Journal of Periodontology, 2022, 93(1): 135-145.

[31] Yao C, Veleva T, Scott Jr L, et al. Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation[J]. Circulation, 2018, 138(20): 2227-2242.

[32] Miyauchi S, Ouhara K, Shintani T, et al. Periodontal Treatment During the Blanking Period Improves the Outcome of Atrial Fibrillation Ablation[J]. Journal of the American Heart Association, 2024, 13(8): e033740.

[33] Packer M. Disease–treatment interactions in the management of patients with obesity and diabetes who have atrial fibrillation: the potential mediating influence of epicardial adipose tissue[J]. Cardiovascular diabetology, 2019, 18(1): 121.

[34] Creta A, Providência R, Adragão P, et al. Impact of type-2 diabetes mellitus on the outcomes of catheter ablation of atrial fibrillation (European Observational Multicentre Study)[J]. The American journal of cardiology, 2020, 125(6): 901-906.

[35] Zhao Z, Jiang C, He L, et al. Impact of Sodium‐Glucose Cotransporter 2 Inhibitor on Recurrence After Catheter Ablation for Atrial Fibrillation in Patients With Diabetes: A Propensity‐Score Matching Study and Meta‐Analysis[J]. Journal of the American Heart Association, 2023, 12(24): e031269.

[36] Ng C Y, Liu T, Shehata M, et al. Meta-analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation[J]. The American journal of cardiology, 2011, 108(1): 47-51.

[37] Fein A S, Shvilkin A, Shah D, et al. Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation[J]. Journal of the American College of Cardiology, 2013, 62(4): 300-305.

[38] Caples S M, Mansukhani M P, Friedman P A, et al. The impact of continuous positive airway pressure treatment on the recurrence of atrial fibrillation post cardioversion: a randomized controlled trial[J]. International journal of cardiology, 2019, 278: 133-136.

[39] Huang B, Liu H, Scherlag B J, et al. Atrial fibrillation in obstructive sleep apnea: Neural mechanisms and emerging therapies[J]. Trends in cardiovascular medicine, 2021, 31(2): 127-132.